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Abstract
Background: Menstrually related migraine (MRM) in the hormone-free interval (HFI) of combined hormonal
contraceptives (CHC) are according to the ICHD definition also estrogen withdrawal migraines (EWH). MRMs are less
responsive to acute medication. Therefore short-term prevention, initiated 1–2 days before onset of the anticipated
bleeding and continued for 6 days, is recommended. Such a long prophylactic triptan use might increase the risk
for medication overuse headache in women suffering in addition from non-menstrual migraines. In CHC users
onset of hormone decline is predictable. It is however unknown, whether the EWHs are rather associated with
onset of hormone withdrawal or onset of bleeding. Improved understanding of this relation might contribute to
better define and shorten the time interval for prevention.
Methods: For this observational diary-based pilot study we collected data from daily conducted headache diaries
of CHC users with MRM in at least two of three cycles, visiting our clinic from 2009 to 2015. We analyzed frequency
of migraines for each hormone free day, onset of migraine, onset of bleeding and the relation of migraine to onset
of bleeding in the 7-day period following estrogen withdrawal. We identified in addition the onset of migraine
attacks lasting more than 1 day (episodes).
Results: Forty patient charts met the inclusion criteria, what allowed us to analyze 103 cycles. The mean number of
migraine days in the HFI was 2.2 ± 1.6. Migraine started typically on days 1–5 and bleeding on days 3–5. In relation
to first day of bleeding, migraines started on days −1 to 4. Almost half of the migraine attacks lasted longer than
24 h, despite the use of rescue medication.
Conclusion: MRM in CHC users starts on bleeding days −1 to 4, what differs from findings in the natural cycle.
Referring to the HFI interval migraine started mostly on days 1–5. According to these data, it seems to be reasonable
to initiate short-term prevention at the last day of pill use or the first day of the HFI and continue for 5 days.
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Background
In women migraine prevalence peaks during reproductive
years [1]. Menstruation is a significant risk factor for mi-
graine with attacks most likely to occur between 2 days
before the onset of menstruation and the first three days
of bleeding. The pathophysiology of menstrual attacks in-
volves estrogen withdrawal and potentially abnormal re-
lease of prostaglandins triggered by the end-cycle drop in
estrogen levels [2, 3]. In addition to menstrually related
migraine (MRM) the ICHD-classification defines estrogen
withdrawal headaches (EWH) as migraines arising in
women using exogenous estrogen daily for three or more
weeks followed by an interruption in which migraine de-
velops within five days after the last estrogen intake [4]. In
general MRMs last longer, are more severe, more disab-
ling and less responsive to acute treatment [5–9]. Short-
term prevention therefore is an important approach for
treatment. Most authors recommend to start preventive
therapy two days before the onset of bleeding [10]. How-
ever, as in the natural cycle onset of bleeding is highly
variable the starting day for prophylactic medications is
difficult to predict. Too early start results in unplanned
and unforeseeable long use of these pain medications. The
latter can result in medication overuse headaches, in those
suffering in addition from non-menstrually related mi-
graines. In combined hormonal contraceptive (CHC)
users however, the day of estrogen withdrawal is clear,
what might facilitate the identification of an optimal inter-
val for short-term prevention. It has however never been
investigated, if onset of EWH in CHC users is more re-
lated to the onset of bleeding or the onset of the
hormone-free time. While in the natural cycle the associ-
ation of bleeding and migraine has been defined as MRM
(days −2 to day 3), the time interval with higher probabil-
ity for EWH in relation to bleeding in CHC users has
never been studied. In contrast to the smooth decline of
estrogen levels, the hormone decline in CHC users pro-
cesses more abrupt and from higher estrogen levels. This
might affect onset and course of the following headache.
Most studies related to MRM characteristics and
treatment do not differentiate women with migraine in
the natural cycle and from CHC users experiencing EWH
[6, 7, 11–14]. The mixture of different headache types in
studies potentially impacts precision of conclusions. With
the present study, we aimed to identify the optimal inter-
val for use of preventive migraine agents in CHC users
with EWH. For this purpose we identified in addition to
migraine days in the pill-free interval, the relationship
between migraine onset and day of last pill intake on one
hand and the first day of bleeding on the other hand.
Methods
Patient charts of all female migraineurs were searched to
identify premenopausal CHC users, who experienced
any migraine in the hormone-free interval (HFI) and vis-
ited our clinic for hormonal migraines (University
Hospital Zürich) from 2009 to 2015. All charts include
headache diaries, which are conducted prospectively
over a period of three cycles, before patients come in for
their first visit and prior to any intervention. This pro-
cedure allows us to identify the type of migraine, espe-
cially MRM and EWH according to ICHD criteria. The
in the retrospect analysed diaries include daily informa-
tion on migraine/headache occurrence, pain intensity,
use of acute medication, use of hormones and vaginal
bleeding. For ethical reasons diaries were anonymized
before evaluation and only the main investigator had ac-
cess to the key and all data. To comply with the ICHD
criteria we included only CHC users with EWH in at
least two of three cycles. A further criterion of inclusion
was use of the CHC in the typical regimen of 21/7 days.
Charts were excluded if women used other types of hor-
monal therapy including progestin-only contraceptives,
CHC regimen different from 21/7 and reported
headaches in only one of three withdrawal periods. Fur-
thermore charts were excluded if women had not yet
used their CHC for at least 6 months.
According to the ICHD definition migraine lasts from 4
to 72 h. As MRM migraines tend to last longer, we evalu-
ated both, migraine days and migraine episodes (lasting
>24 h). To identify onset of bleeding, migraine days, the
first day of migraine and the start of migraine episodes we
collected data during days 1–7 of the HFI. To explore the
vulnerable time frame for migraine onset in relation to the
withdrawal bleeding we choose the interval of days −3 to
day 5, which allowed us to exclude that we might miss an
association by just including two days before bleeding and
the first three bleeding days. A similar procedure has been
used earlier by MacGregor [15].
Statistical analyses
The programs IBM SPSS Statistics 22 and Excel 2013
were used for the statistical evaluation of this project.
Continuous demographic and clinical characteristics are
presented as means and standard deviations (SD).
Frequencies and percentages were used to describe
migraine days, migraine episodes and bleeding days over
the described time intervals. For these comparisons
chi-square test was used.
Results
We identified 92 CHC users out of 177 patient charts
from all premenopausal female migraineurs visiting our
clinic between 2009 and 2015. Forty met all inclusion
criteria and were eligible for evaluation. From the ex-
cluded patients 27 had not conducted complete diaries
over 3 cycles or had used CHC continuously (long-
cycle), 11 patients used CHC regimen different from 21/
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7 and 14 patients had suffered from migraine only in
one out of three cycles. As at present there is no evi-
dence that CHC-related estrogen-withdrawal headache
is influenced by the progestin-type, CHC with all types
of progestins were included. In the present study these
were levonorgestrel, desogestrel, drospirenone, gestoden
and cyproterone-acetate. The daily ethinylestradiol
dosage ranged from 20 to 30 μg. In total data of 103 cy-
cles were eligible for analyses. Twenty-three patients ex-
perienced migraine in all three cycles, while 17 patients
suffered from migraine in only two out of three cycles.
All patients had started their CHC more than 6 months
before inclusion. Mean age of the forty included patients
was 29.1 (18–40) years. The mean number of migraine
days during the HFI was 2.2 ± 1.6 (mean ± SD). Mi-
graine without aura was more common than migraine
with aura in the history of the patients with a total of 33
patients (82.5%) versus 7 patients (17.5%). Migraine epi-
sodes were observed in 49% of all cycles. Most with-
drawal bleedings started at day 4 of the HFI (39.2% of
cycles) (Fig. 1). In 84.3% of the cycles the first day of
withdrawal bleeding was reported on pill-free days 3 to
5. The first bleeding day in the HFI varied one day in
75% of the migraineurs and two days or less from cycle
to cycle in more than 90% of the women and insofar
was much better predictable in comparison with the nat-
ural cycle. The frequency of all migraines at each day of
the HFI is demonstrated in Fig. 2. It increased from day
two onward and was above 32% on days 3–7. The days
with highest percentages of migraine attacks were days 5
and 6 with 36.9% of cycles each closely followed by the
days 3 and 4 (34%) and day 7 (33%). Migraine onset in
the HFI was mostly on days 1–5 (Fig. 1). Alike the start
of migraine episodes was typically at days 1–5 and rarely
during days six and seven (Fig. 3). In relation to the start
of withdrawal bleeding migraine frequency started to rise
at day one before bleeding (31.7% of the cycles) (Fig. 4).
In more than 40% of the analyzed cycles migraine at-
tacks occurred on bleeding days 1, 2, 3 and 4.
Discussion
In the present study we analyzed the onset and course of
single migraine days and migraine episodes during the
HFI in CHC users. In the latter migraine could be asso-
ciated with either, the sharp hormone decline immedi-
ately after stopping the pill or with the onset of
withdrawal bleeding some days later. To optimize the
duration of short-term prevention and avoid medication
overuse headaches in women suffering in addition from
non-menstrual related attacks this issue is of relevance.
Analyses of headaches and bleeding over the seven
hormone-free days revealed that bleeding mostly starts
during days 3–5 and onset is in contrast to the natural
cycle highly predictable. The first migraine attack
occured on days 1–5 (each 12–20% of cycles), indicating
that prevention has to start earlier than the expected
withdawal bleeding (Fig. 1). Migraine start at days 1–5 is
in accordance with the 5-day period defined for
estrogen-withdrawal headaches by the ICHD. Most mi-
graine days were observed on days 3–7 (each in more
than 33% of cycles, Fig. 2). In relation to withdrawal
bleeding most migraines occurred between day −1 and
day 4. There was a twofold frequency of migraine attacks
Fig. 1 First day of bleeding and first migraine day in the seven days of the hormone-free interval of combined hormonal contraceptive users
Fig. 2 Frequency of migraine days in the seven days of the
hormone-free interval of combined hormonal contraceptive users
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on bleeding days 1–4 in comparison to day −2 in our
study. This differs from previous studies exploring MRM
in the natural cycle, which identified peaks of attacks
from bleeding days −2 to day 3 and is exactly one day
later, in comparison to the ICHD definition [6, 16]. The
abrupt estrogen decline in women stopping use of ex-
ogenous applied estrogens together with its effects on
bleeding could explain this difference. Also preliminary
this finding suggests that using the same time frame for
both, MRM in the natural cycle and after use of artificial
estrogens in CHC users might be too imprecise.
MRMs have been found to be longer lasting, more se-
vere and refractory to abortive medications [6, 17]. As
the majority of our study participants suffered from both
MRM and non-menstrually related migraine attacks we
cannot exclude that some of the migraine attacks during
the HFI are only randomly associated with hormone
withdrawal. Separate analyses of longer lasting attacks
might provide a better approach to identify truly hor-
mone- withdrawal associated migraines. Episodes (at-
tacks lasting >1 day) in our study were observed in 49%
of 103 cycles with a mean duration of more than 3 days,
in spite of use of rescue medication. The high rate of
long lasting episodes of EWH in CHC users indicates
that these headaches similar as the MRM in the natural
cycle, are also long lasting and less responsiveness to
rescue medication [6, 7]. Most of these episodes started
on days 1–5 of the HFI, as well.
To our knowledge this is the first study analyzing the
course of migraine during the hormone-free interval in
CHC users, which includes in accordance with the ICHD
criteria only women with EWM in at least two of three cy-
cles. One study, including women with MRM in the HFI
reported highest pain scores at HFI day 4 in eleven CHC
users, but was limited with regard to the low number of
CHC users and the observation period of only one cycle
[18]. Lieba-Samal et al. investigated prevalence of head-
ache and migraine in CHC users in association with their
withdrawal bleeding [19]. They found that CHC users had
a twofold hazard ratio for migraines at bleeding days 1–3,
but not at days −1/−2. Inclusion criteria comprised at least
one day of migraine per month, without consideration of
the HFI. We in addition to bleeding days 1–3 observed
more migraine attacks at days -1and day 4. Our daily ana-
lyses of headache days over days −3 to day 5 is not com-
parable with the mentioned interval analyses and much
more exact for the objective. Numerous studies demon-
strated that MRM attacks last longer in comparison to
non-menstrual migraine attacks [7, 20]. Characteristics of
migraine attacks are highly variable not only among pa-
tients but also within the same patient [21]. For preventive
therapy of EWH the majority of medications have been
tested to be started two days before the expected onset of
menstrual flow and to be continued for 6 days [10, 22–
24]. The low predictability of bleeding and hormone with-
drawal in the natural cycle makes it difficult to apply to
such a regimen and frequently results in treatment periods
of 8 and more days [15]. In women with additional non-
menstrual attacks this may cause an unacceptable high
use of rescue medications. Our data demonstrate that first
day of migraine and migraine episodes rarely occur later
than day 6 of the HFI. Referring to our results it appears
to be reasonable to initiate short-term prevention in CHC
users at the last day of pill intake or the first day of the
HFI and continue for 5 days. Even if withdrawal bleeding
in CHC users is highly predictable, our data indicate that
use of the HFI as reference point is the better choice.Start-
ing prevention at the last day of pill intake would also be
optimal to prevent most of the episodes, which are very
disabling, long-lasting and difficult to treat.
Strengths of the current study include the exact diag-
nosis of menstrually related migraine according to the
ICHD-criteria, the accurate prospectively conducted
daily diaries, the inclusion of only women with the typ-
ical 21/7 CHC regimen and the headache documenta-
tion over three cycles. Analyzing first days of migraine
episodes increases the probability to identify the onset of
true menstrually related attacks with low responsiveness
to abortive medications. Analyses of the reproducibility
Fig. 4 Migraine attacks in combined hormonal contraceptive users
in relation to start of bleeding during days −3 to day 5
Fig. 3 First migraine episode at each day of the hormone-free interval
of combined hormonal contraceptive users
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of the first bleeding day over several cycles might
contribute to optimize treatment in some women. A po-
tential limitation is the evaluation of the diaries in the
retrospect. We cann’t exclude that inclusion of CHC
containing different ethinylestradiol dosages (20 μg and
30 μg) might exert an impact on our results. Ethinyles-
tradiol is much more potent than the naturally released
estradiol. With both CHC dosages, estrogen withdrawal
occurs from higher estrogen levels and is much more
abrupt in comparison to the natural cycle. Therefore we
do not think that the small differences in ethinylestradiol
dosage are relevant in the context of this study. The
number of more than 100 evaluated cycles is sufficient
for a pilot study, but the results have to be confirmed in
prospectively conducted studies including more cycles.
Data from women attending a specialist migraine office
cannot always be extrapolated to the general populatio-
n.Even taking into account these limitations we consider
the present data as useful to clinicians who treat CHC
users with EWH and have to define the time frame for
short-term prevention. In this context it has to be men-
tioned that treatment of migraine in CHC users should
not only imply rescue medications or prophylactic
agents, but also the consideration to change to a proges-
tin- only method. These are not only safer but may
reduce migraine frequency and intensity as well [25–32].
Use of CHC in extended cycles regimen is another ap-
proach to improve withdrawal migraine but is not rec-
ommended, as risk of breast cancer with those pill
regimen is unknown and risk for ischemic stroke could
further increase [16, 22, 30]. For women with MRM a
multidisciplinary approach combining neurological and
gynaecological consultations might be of advantage [33].
Conclusions
In CHC users migraine mostly starts on bleeding days −1
to day 4, what differs from findings in the natural cycle.
Referring to the HFI interval most migraines and migraine
episodes start at days 1–5. Around 50% of the migraine at-
tacks last more than 24 h. Short-term prevention could
contribute to better management of these episodes and
should be initiated at the last day of pill use or the first
day of the HFI and be continued for 5 days.
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